NCT02481297 2020-05-28Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsM.D. Anderson Cancer CenterPhase 2 Completed7 enrolled 11 charts
NCT02599649 2020-01-14Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer CenterPhase 2 Terminated10 enrolled 8 charts